Taisho Buys Biofermin In All-Japanese Acquisition
This article was originally published in PharmAsia News
Japan's Taisho Pharmaceutical has bought a controlling interest in Biofermin Pharmaceutical for $240.2 million. The Taisho purchase amounts to a 54.8 percent stake in Biofermin, which Taisho plans to make a subsidiary. Biofermin has a marketing agreement with Takeda Pharmaceutical, which opposed the Taisho bid, but that contract is to remain in place. The acquiring company plans to develop lactobacillus products, using Biofermin facilities. (Click here for more - may require a subscription
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.